CN104558199B - 一种治疗高胆固醇血症的融合蛋白制备及其用途 - Google Patents
一种治疗高胆固醇血症的融合蛋白制备及其用途 Download PDFInfo
- Publication number
- CN104558199B CN104558199B CN201410454292.6A CN201410454292A CN104558199B CN 104558199 B CN104558199 B CN 104558199B CN 201410454292 A CN201410454292 A CN 201410454292A CN 104558199 B CN104558199 B CN 104558199B
- Authority
- CN
- China
- Prior art keywords
- fusion protein
- pcsk9
- ldl
- megf
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108020001507 fusion proteins Proteins 0.000 title claims abstract description 39
- 102000037865 fusion proteins Human genes 0.000 title claims abstract description 38
- 208000035150 Hypercholesterolemia Diseases 0.000 title claims abstract description 8
- 238000002360 preparation method Methods 0.000 title description 4
- 101001098868 Homo sapiens Proprotein convertase subtilisin/kexin type 9 Proteins 0.000 claims abstract description 31
- 102100038955 Proprotein convertase subtilisin/kexin type 9 Human genes 0.000 claims abstract description 31
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 5
- 206010045261 Type IIa hyperlipidaemia Diseases 0.000 claims abstract description 3
- 102100024640 Low-density lipoprotein receptor Human genes 0.000 claims abstract 3
- 208000000563 Hyperlipoproteinemia Type II Diseases 0.000 claims abstract 2
- 201000001386 familial hypercholesterolemia Diseases 0.000 claims abstract 2
- 238000000034 method Methods 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 229940079593 drug Drugs 0.000 claims description 4
- 239000007924 injection Substances 0.000 claims description 4
- 238000002347 injection Methods 0.000 claims description 4
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims description 3
- 208000016097 disease of metabolism Diseases 0.000 claims description 3
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims description 3
- 208000030159 metabolic disease Diseases 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- 238000005215 recombination Methods 0.000 claims description 3
- 230000006798 recombination Effects 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 230000006698 induction Effects 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract description 9
- 108010007622 LDL Lipoproteins Proteins 0.000 abstract description 7
- 102000007330 LDL Lipoproteins Human genes 0.000 abstract description 7
- 210000005229 liver cell Anatomy 0.000 abstract description 7
- 230000015556 catabolic process Effects 0.000 abstract description 5
- 238000006731 degradation reaction Methods 0.000 abstract description 5
- 229920001184 polypeptide Polymers 0.000 abstract description 5
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 5
- PXFBZOLANLWPMH-UHFFFAOYSA-N 16-Epiaffinine Natural products C1C(C2=CC=CC=C2N2)=C2C(=O)CC2C(=CC)CN(C)C1C2CO PXFBZOLANLWPMH-UHFFFAOYSA-N 0.000 abstract description 3
- 201000010099 disease Diseases 0.000 abstract description 3
- 108010001831 LDL receptors Proteins 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 25
- 239000013612 plasmid Substances 0.000 description 16
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 14
- 108090000623 proteins and genes Proteins 0.000 description 14
- 239000012634 fragment Substances 0.000 description 13
- 108010028554 LDL Cholesterol Proteins 0.000 description 11
- 230000029087 digestion Effects 0.000 description 11
- 241000894006 Bacteria Species 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 10
- 230000000694 effects Effects 0.000 description 9
- 230000002068 genetic effect Effects 0.000 description 8
- 239000002773 nucleotide Substances 0.000 description 8
- 125000003729 nucleotide group Chemical group 0.000 description 8
- 239000000872 buffer Substances 0.000 description 7
- 238000012216 screening Methods 0.000 description 7
- 150000001413 amino acids Chemical class 0.000 description 6
- 235000012000 cholesterol Nutrition 0.000 description 6
- 239000013604 expression vector Substances 0.000 description 6
- 239000008280 blood Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 238000000246 agarose gel electrophoresis Methods 0.000 description 4
- 239000007853 buffer solution Substances 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 230000007850 degeneration Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 239000002547 new drug Substances 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000012549 training Methods 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 101100230376 Acetivibrio thermocellus (strain ATCC 27405 / DSM 1237 / JCM 9322 / NBRC 103400 / NCIMB 10682 / NRRL B-4536 / VPI 7372) celI gene Proteins 0.000 description 1
- 241000208340 Araliaceae Species 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- -1 EGF amino acid Chemical class 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 108091006020 Fc-tagged proteins Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- 240000000220 Panda oleosa Species 0.000 description 1
- 235000016496 Panda oleosa Nutrition 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 108010044159 Proprotein Convertases Proteins 0.000 description 1
- 102000006437 Proprotein Convertases Human genes 0.000 description 1
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 108090000787 Subtilisin Proteins 0.000 description 1
- 108700005078 Synthetic Genes Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 229960004539 alirocumab Drugs 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 229960002027 evolocumab Drugs 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 201000005577 familial hyperlipidemia Diseases 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 230000009368 gene silencing by RNA Effects 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000005305 interferometry Methods 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 238000005374 membrane filtration Methods 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 208000021090 palsy Diseases 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 229950010131 puromycin Drugs 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940126622 therapeutic monoclonal antibody Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Abstract
Description
重组融合蛋白 | KD值(nM) |
EGFwt-Fc | 798±90 |
mEGF14-Fc | 121±14 |
mEGF16-Fc | 58±9 |
3mEGF-Fc | 17±4 |
Claims (8)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410454292.6A CN104558199B (zh) | 2014-09-05 | 2014-09-05 | 一种治疗高胆固醇血症的融合蛋白制备及其用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410454292.6A CN104558199B (zh) | 2014-09-05 | 2014-09-05 | 一种治疗高胆固醇血症的融合蛋白制备及其用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104558199A CN104558199A (zh) | 2015-04-29 |
CN104558199B true CN104558199B (zh) | 2018-07-06 |
Family
ID=53075348
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410454292.6A Active CN104558199B (zh) | 2014-09-05 | 2014-09-05 | 一种治疗高胆固醇血症的融合蛋白制备及其用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104558199B (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108623672A (zh) * | 2017-03-25 | 2018-10-09 | 成都贝爱特生物科技有限公司 | 新的egf-a和b的组合突变体制备及其在生物药物中的应用 |
AR116605A1 (es) | 2018-10-05 | 2021-05-26 | Novo Nordisk As | Compuestos bifuncionales que comprenden péptidos de insulina y péptidos de egf(a) |
CN109295081B (zh) * | 2018-10-17 | 2020-06-12 | 中国人民解放军第四军医大学 | 一种LDLR-Lamp2b融合基因、表达载体及其应用 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101003568A (zh) * | 2006-12-20 | 2007-07-25 | 吉林农业大学 | 重组白喉毒素及其制备方法和应用 |
CN102232088A (zh) * | 2007-10-26 | 2011-11-02 | 先灵公司 | 用于治疗脂类和胆固醇疾病的抗pcsk9及方法 |
CN102612558A (zh) * | 2009-09-03 | 2012-07-25 | 辉瑞疫苗有限责任公司 | Pcsk9疫苗 |
WO2013170367A1 (en) * | 2012-05-17 | 2013-11-21 | The University Of British Columbia | Methods and uses for proprotein convert ase subtilisin kexin 9 (pcsk9) inhibitors |
-
2014
- 2014-09-05 CN CN201410454292.6A patent/CN104558199B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101003568A (zh) * | 2006-12-20 | 2007-07-25 | 吉林农业大学 | 重组白喉毒素及其制备方法和应用 |
CN102232088A (zh) * | 2007-10-26 | 2011-11-02 | 先灵公司 | 用于治疗脂类和胆固醇疾病的抗pcsk9及方法 |
CN102612558A (zh) * | 2009-09-03 | 2012-07-25 | 辉瑞疫苗有限责任公司 | Pcsk9疫苗 |
WO2013170367A1 (en) * | 2012-05-17 | 2013-11-21 | The University Of British Columbia | Methods and uses for proprotein convert ase subtilisin kexin 9 (pcsk9) inhibitors |
Non-Patent Citations (3)
Title |
---|
A PCSK9-binding antibody that structurally mimics the EGF(A) domain of LDL-receptor reduces LDL cholesterol in vivo;Yan G. Ni;《Journal of Lipid Research 》;20101019;第52卷;78-86 * |
Structural and Biochemical Characterization of the Wild Type PCSK9-EGF(AB) Complex and Natural Familial Hypercholesterolemia Mutants;Matthew J. Bottomley;《THE JOURNAL OF BIOLOGICAL CHEMISTRY》;20090109;第284卷(第2期);1313–1323 * |
多肽基因串联体构建技术;刘宝全;《安徽农业科学》;20101231;第38卷(第16期);8345 -8346 * |
Also Published As
Publication number | Publication date |
---|---|
CN104558199A (zh) | 2015-04-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1314705C (zh) | 高效抑制血管生成多肽及其制备方法和应用 | |
JP6071099B1 (ja) | 血管の新生又は成長を抑制する融合タンパク質及びその用途 | |
Sekhon | Biopharmaceuticals: an overview | |
CN108472337A (zh) | 因子ix融合蛋白以及其制备和使用方法 | |
CN104558199B (zh) | 一种治疗高胆固醇血症的融合蛋白制备及其用途 | |
UA47428C2 (uk) | Спосіб контролю кількості сіалової кислоти, спосіб одержання химерного глікопротеїну (варіанти), препарат, що містить химерний глікопротеїн (варіанти), терапевтична композиція | |
CN101535469A (zh) | 合理设计的细胞培养基 | |
CN105037554B (zh) | 抗人pcsk9抗体的制备及其用途 | |
JP2008520222A (ja) | 変異ネトリン4、その断片及びこれらの薬剤としての使用 | |
Beatson et al. | Transforming growth factor‐β1 is constitutively secreted by chinese hamster ovary cells and is functional in human cells | |
CN107698680A (zh) | 抗pcsk9单克隆抗体 | |
JP2022512843A (ja) | スフィンゴシンキナーゼ1とその融合タンパク質およびその使用 | |
CN109402130A (zh) | 一种重组人角质细胞生长因子-1及其制备方法和用途 | |
CN101245106B (zh) | 抗vegf受体单克隆抗体及其制备方法和应用 | |
CN108642070B (zh) | 特异性诱导肿瘤细胞凋亡的重组人Fc抗体及其制备方法、用途 | |
CN106795222A (zh) | 用结合集落刺激因子1受体(csf1r)的抗体治疗病状的方法 | |
CN101684156B (zh) | 人TNFα单克隆抗体、其PEG化纳米颗粒及其应用 | |
CN105111315A (zh) | MIP3α-Fc融合蛋白及其用途 | |
CN1740197B (zh) | 具有全新空间构象且功效增强的重组干扰素、其制备方法及应用 | |
CN108101984B (zh) | 骨硬化蛋白单链抗体的制备方法和用途 | |
CN113698486A (zh) | Mmp-9纳米抗体及其制备方法与应用 | |
CN109394786A (zh) | 一种抗肿瘤的药物组合物 | |
CN102241776B (zh) | Rankl-tnf样区融合蛋白及其制备方法和应用 | |
US20240018206A1 (en) | An interleukin-1 receptor antagonist and a fusion protein containing the same | |
CN104450781A (zh) | 一种过表达ciapin1蛋白的细胞系及其制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20170602 Address after: 610036 Jinniu District, Sichuan, Sichuan West Road, No. 36, No. Applicant after: CHENGDU KANGHONG BIOTECHNOLOGIES Co.,Ltd. Address before: 610041 No. 404, building C1, Tianfu Life Science Park, 88 South Garden Road, Chengdu hi tech Zone, Sichuan, China Applicant before: CHENGDU BIPROTEIN BIOTECHNOLOGY CO.,LTD. |
|
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20231027 Address after: Room 306, Building 2, No. 88 Kechuang 6th Street, Beijing Economic and Technological Development Zone, Daxing District, Beijing, 100176 Patentee after: Beijing Kanghong Biomedical Co.,Ltd. Address before: 610036 No. 36 Shu West Road, Chengdu, Sichuan, Jinniu District Patentee before: CHENGDU KANGHONG BIOTECHNOLOGIES Co.,Ltd. |